Argenica Secures Xaranetide as Global Name for Lead Stroke Drug ARG-007
World Health Organisation confirms xaranetide as proposed INN for Argenica’s lead stroke drug
The World Health Organisation (WHO) has confirmed xaranetide (pronounced “za-RAN-e-tide”) as the proposed International Nonproprietary Name (INN) for Argenica Therapeutics (ASX: AGN)‘s lead neuroprotective drug candidate, ARG-007. Following completion of the public consultation period, no objections were noted against the proposed name, marking a key regulatory milestone for the clinical-stage biotechnology company’s acute stroke therapy.
The WHO INN Programme evaluates proposed names through a formal review process before publication in the WHO List of Proposed INNs. Xaranetide will now become the recognised generic name for ARG-007 across regulatory, scientific and medical communities globally. Publication in the WHO List of Recommended INNs is expected shortly.
For investors, INN confirmation signals regulatory maturation of the clinical asset and positions Argenica for streamlined engagement with global regulators and potential commercial partners. The establishment of a globally recognised generic name facilitates regulatory filings, clinical trial documentation, scientific literature and commercial discussions as the drug advances through clinical development.
When big ASX news breaks, our subscribers know first
What is an International Nonproprietary Name and why it matters
An International Nonproprietary Name is a unique generic name assigned by the WHO to pharmaceutical substances to ensure global identification. The INN system provides a standardised naming framework that enables healthcare professionals, regulators and researchers to identify active pharmaceutical ingredients consistently across different countries and languages.
The formal review process follows a structured pathway: proposed name → public consultation → recommended INN status → publication. During the consultation period, national nomenclature committees, pharmaceutical companies and other stakeholders may raise objections if the proposed name creates confusion with existing medicines or raises safety concerns. Xaranetide completed this process with no objections expressed.
INNs are used across regulatory filings, clinical trial documentation, scientific literature and commercial agreements worldwide. For investors, INN assignment typically occurs as a drug advances through clinical development, indicating the asset has reached sufficient maturity to warrant a formal global identifier. This step is generally taken by drug candidates progressing toward late-stage trials and regulatory submissions, rather than early-stage research compounds.
Argenica’s neuroprotection platform targets acute stroke
Argenica is a clinical-stage biotechnology company developing innovative neuroprotective therapeutics to improve outcomes for patients following stroke and other acute neurological injuries. Xaranetide (formerly ARG-007) is designed to protect vulnerable brain tissue by reducing cell death and limiting secondary damage after an ischemic event.
Key facts:
- Clinical stage: Clinical-stage biotechnology company
- Therapeutic focus: Acute stroke and neurological injuries
- Lead candidate: Xaranetide (ARG-007)
- Mechanism: Neuroprotection – reduces cell death after ischemic event
The company will now begin to include xaranetide in various communications.
Phase 2b trial design has been sharpened by a six-member Clinical Advisory Committee including internationally recognised specialists such as Prof Geoffrey Donnan and Prof Jeffrey Saver, whose input on endpoint selection, patient criteria and dosing strategy directly shapes the probability of clinical success.
Management commentary
Dr Liz Dallimore, Managing Director
“The proposal of xaranetide as the INN for ARG-007 represents an important milestone in the maturation of our lead clinical asset. Establishing a globally recognised generic name is a key step as we continue advancing ARG-007 through clinical development and engage with regulators, investigators and future commercial partners worldwide.”
The next major ASX story will hit our subscribers first
Next steps for Argenica
Publication in the WHO List of Recommended INNs is expected shortly, completing the formal INN assignment process. The formalisation of a global generic name positions Argenica for streamlined regulatory discussions and partnership negotiations as clinical development progresses.
The company continues to advance xaranetide through its clinical development pathway, with the formal INN providing a standardised identifier for use across regulatory submissions, investigator communications and commercial discussions with potential partners globally.
FDA safety clearance progress has been advancing in parallel, with two of three required studies now complete and only the GLP hERG cardiac assay remaining before Argenica can submit a full clinical hold response to unlock its Phase 2b US trial.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get healthcare and biotech announcements delivered straight to your inbox the moment market-moving developments break.